Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

3.565 +0.075 (+2.15%)
Streaming Delayed Price Updated: 10:24 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week
Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week. 
Via Talk Markets
The Latest Analyst Ratings for Compass Pathways
Via Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
Via Talk Markets
COMPASS' Securities Purchase Agreement Is Big News
It’s still cannabis earnings season, but we’re also turning to look at some of the news from the psychedelics industry. ... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Up To $285M In Financing: COMPASS Pathways' Private Placement Backed By 'Select Group' Of Investors
Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group of... 
Via Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. 
Via Talk Markets
Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA
Atai Life Sciences (NASDAQ: ATAI) reported its consolidated, unaudited financial results for the second quarter 2023 ended June 30. Numbers show: 
Via Benzinga
Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript
CMPS earnings call for the period ending June 30, 2023. 
Via The Motley Fool
COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And 'Strong Progress Across The Business'
Psychedelics biotech COMPASS Pathways’ (NASDAQ: CMPS) consolidated unaudited financial results for the second quarter 2023, ended June 30 are as follows: 
Via Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: 
Via Talk Markets
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock
For biotechs developing psychedelic therapies, good news comes in many forms. 
Via The Motley Fool
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
Compass' Psilocybin Therapy Proves Helpful In Treating Anorexia: Clinical Trial Shows
UC-San Diego authors assessed psilocybin therapy’s potential as a treatment for anorexia nervosa. They recently shared what are believed to be the first results from such a research study, and the... 
Via Benzinga
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
By Rachael Green, Benzinga 
Via TheNewswire.com
Exposures Product Safety
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
--News Direct-- 
Via News Direct
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal... 
Via Benzinga
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
The American Medical Association’s (AMA) Panel recently released the full details of a new code for psychological support during the administration of psychedelic treatments. 
Via Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug... 
Via Talk Markets
Jim Cramer Says It's Time To Buy This Financial Services Stock Down 32% YTD
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. (NASDAQ: ILMN) is not even as good as Danaher Corporation (NYSE: DHR). 
Via Benzinga
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
COMPASS Pathways (NASDAQ: CMPS) shared results from an open-label Phase 2 trial assessing its synthetic psilocybin COMP360 alongside SSRIs for Treatment-Resistant Depression (TRD.) 
Via Benzinga
Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD
Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD. 
Via Talk Markets
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market. 
Via Benzinga
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... 
Via Benzinga
Top 5 Health Care Stocks That May Collapse This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Psychedelic Stocks Jumped 10% Last Week
The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly 
Via Talk Markets
Why iMedia Brands Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Prestige Wealth Inc. (NASDAQ: PWM) shares jumped 65.6% to $8.28. Prestige Wealth reported pricing of $5 million initial public offering of 1 million shares of common stock at a price of $5 per... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.